Novo Nordisk (NYSE:NVO) said Tuesday that Health Canada has expanded the label for its diabetes therapy Ozempic, granting approval for use in patients with chronic kidney disease.

The new indication allows physicians to prescribe Ozempic to help slow the progression of kidney impairment, reduce the risk of kidney failure, and lower the likelihood of cardiovascular-related death in diabetes patients also suffering from chronic kidney disease.

According to the company, this marks the first treatment authorized in Canada to address both type 2 diabetes management and kidney disease progression under a single therapy.

Ozempic, part of the GLP-1 drug class, received comparable approval in the United States earlier in 2025 for the same kidney-related use.

Novo Nordisk stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Join the discussion: Connect with other investors on your favorite stocks or explore the top-talked-about stocks on our Breakout Boards.

This article was written by the editorial team at InvestorsHub/ADVFN and is provided for informational purposes only. In some cases, editorial staff may use artificial intelligence–based tools to assist in the research, drafting, or editing of content, under human review and oversight. This article does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. The views expressed are based on publicly available information believed to be reliable at the time of publication, but accuracy or completeness is not guaranteed. Readers should conduct their own independent research and consult a qualified financial professional before making any investment decisions.